The Mount Sinai Health System has appointed three new chief medical officers to lead The Mount Sinai Hospital, Mount Sinai Beth Israel, and Mount Sinai Queens.
Vicki LoPachin, MD, a respected member of the medical community who completed her residency and chief residency in internal medicine at Mount Sinai, recently returned to The Mount Sinai Hospital to serve as Chief Medical Officer.
Nobel Laureate Günter Blobel, MD, PhD, known for his pioneering research in cell biology, was the keynote speaker at the recent Tenth Annual Dr. Nina Poretsky and Ruvim Poretsky Memorial Lecture at Mount Sinai Beth Israel.
Icahn School of Medicine at Mount Sinai and The New York Academy of Medicine (NYAM) announced the formation of a new partnership to jointly study and address a number of significant health issues and policies that impact the lives of people who live in urban areas. NYAM is an historic and independent institution that has been advancing the health of people living in cities since its founding in 1847.
In February, CBS This Morning had a segment on Mount Sinai’s novel use of fruit flies to screen for personalized cancer drugs. Ross Cagan, PhD, Associate Dean of the Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, discussed how his laboratory replicates a patient’s tumor and implants it in a fruit fly. Then his team tests an arsenal of 840 drugs—all approved by the U.S. Food and Drug Administration for other uses—to see if they shrink the tumor.
“Philanthropy in an academic medical center such as the Mount Sinai Health System helps improve patient care and provides necessary funding for the innovative treatments that answer society’s pressing health care needs,” according to leaders of Mount Sinai, who recently appeared on a special edition of CNBC’s television show Squawk Box to discuss their support.
The most recent study from the Seaver Autism Center at Mount Sinai draws a possible link between the genetic abnormalities attributed to autism spectrum disorder (ASD), and dysregulation of the mechanism by which unused neural connections are pruned during development. This information builds upon prior discoveries at the Seaver Center, which identified three kinds of genetic mutations that are believed to contribute to autism risk: de novo mutations; recessive or X-linked mutations; and small chromosomal abnormalities.